Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Exchange Rate Effect (2024 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Exchange Rate Effect for 2 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly Exchange Rate Effect fell 242.53% to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$233000.0 through Dec 2025, up 50.43% year-over-year, with the annual reading at -$233000.0 for FY2025, 50.43% up from the prior year.
  • Exchange Rate Effect hit -$1.4 million in Q4 2025 for Ani Pharmaceuticals, down from $576000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $841000.0 in Q2 2025 to a low of -$1.4 million in Q4 2025.